Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer.

Sanders LM, Kell BA, McRae GI, Whitehead GW

Journal of pharmaceutical sciences1 Apr 1986Cited by 66 (Europe PMC)

PMID2941563DOI10.1002/jps.2600750407PepBankPUB-02941563

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, nafarelin-loaded polymeric implants provided essentially continuous efficacy for greater than eight months.
In plain wordsIn rats, nafarelin-loaded implants provided essentially continuous effects for more than eight months.
Peptide
Nafarelin
Outcome
Not applicableContinuous efficacy
Study
ratn: not reported in source
Rat implant model
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
A system has been identified in which the secondary phase is sufficiently reduced to provide essentially continuous efficacy in the rat for greater then eight months, with partially effective levels of release of nafarelin continuing beyond 15 months.
Report a problemFND-0294156306
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, nafarelin-loaded polymeric implants maintained partially effective release beyond 15 months.
In plain wordsIn rats, nafarelin-loaded implants maintained partially effective drug release beyond 15 months.
Peptide
Nafarelin
Outcome
Not applicablePartially effective release
Study
ratn: not reported in source
Rat implant model
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
A system has been identified in which the secondary phase is sufficiently reduced to provide essentially continuous efficacy in the rat for greater then eight months, with partially effective levels of release of nafarelin continuing beyond 15 months.
Report a problemFND-0294156307

Studies that did not test the peptide alone5

In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Nafarelin.

03LabNot a test of Nafarelin aloneOther designPharmacokinetics
In formulation tests, nafarelin-loaded PLGA implants showed a triphasic release profile with lower release between higher-release phases.
In plain wordsIn lab tests, nafarelin-loaded implants released less drug between two phases of greater release.
Peptide
Nafarelin
Outcome
Not applicableTriphasic release
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
The release has a triphasic profile typical for bulk-eroding monolithic controlled-release systems, characterized by a secondary phase of lower release preceded and followed by phases of higher release.
1 context sentence(design, population, supporting numbers)
Title · context
Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0294156301
04LabNot a test of Nafarelin aloneOther designPharmacokinetics
In formulation tests, polymer erosion was the primary factor controlling release from nafarelin-loaded implants.
In plain wordsIn lab tests, polymer erosion mainly controlled nafarelin release from implants.
Peptide
Nafarelin
Outcome
Not applicablePolymer erosion and release
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
The primary factor controlling the peptide release profile is polymer erosion, which in turn may be controlled by modifying physical properties of the polymer such as the molecular weight or the ratio of the more hydrophobic lactic acid monomer to the less hydrophobic glycolic acid monomer.
1 context sentence(design, population, supporting numbers)
Title · context
Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0294156302
05LabNot a test of Nafarelin aloneOther designPharmacokinetics
In formulation tests, the secondary release phase of nafarelin-loaded implants increased in duration in proportion to copolymer molecular weight.
In plain wordsIn lab tests, heavier copolymers prolonged the lower-release phase of nafarelin-loaded implants.
Peptide
Nafarelin
Outcome
IncreaseMolecular weight and secondary phase
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
The duration of the secondary phase has been found to be directly proportional to the molecular weight of the copolymer, and the total duration as well as the duration of the secondary phase are both directly proportional to the monomer ratio.
1 context sentence(design, population, supporting numbers)
Title · context
Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0294156303
06LabNot a test of Nafarelin aloneOther designPharmacokinetics
In formulation tests, total release duration from nafarelin-loaded implants increased in proportion to the monomer ratio.
In plain wordsIn lab tests, a higher monomer ratio prolonged total release from nafarelin-loaded implants.
Peptide
Nafarelin
Outcome
IncreaseMonomer ratio and release duration
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
The duration of the secondary phase has been found to be directly proportional to the molecular weight of the copolymer, and the total duration as well as the duration of the secondary phase are both directly proportional to the monomer ratio.
1 context sentence(design, population, supporting numbers)
Title · context
Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0294156304
07LabNot a test of Nafarelin aloneOther designPharmacokinetics
In formulation tests, the secondary release phase of nafarelin-loaded implants increased in duration in proportion to the monomer ratio.
In plain wordsIn lab tests, a higher monomer ratio prolonged the lower-release phase of nafarelin-loaded implants.
Peptide
Nafarelin
Outcome
IncreaseMonomer ratio and secondary phase
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
The duration of the secondary phase has been found to be directly proportional to the molecular weight of the copolymer, and the total duration as well as the duration of the secondary phase are both directly proportional to the monomer ratio.
1 context sentence(design, population, supporting numbers)
Title · context
Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer.
In this study, Nafarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Nafarelin.
Report a problemFND-0294156305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.